Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ulrike Heinicke"'
Autor:
Ulrike Heinicke, Elisabeth Adam, Michael Sonntagbauer, Andreas von Knethen, Kai Zacharowski, Holger Neb
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-4 (2020)
Externí odkaz:
https://doaj.org/article/1b46a035cd56448a99aea107d8770ad4
Autor:
Matthias Piesche, Jessica Roos, Benjamin Kühn, Jasmin Fettel, Nadine Hellmuth, Camilla Brat, Isabelle V. Maucher, Omar Awad, Carmela Matrone, Simon Gabriel Comerma Steffensen, Georg Manolikakes, Ulrike Heinicke, Kai D. Zacharowski, Dieter Steinhilber, Thorsten J. Maier
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Nitro fatty acids (NFAs) are endogenously generated lipid mediators deriving from reactions of unsaturated electrophilic fatty acids with reactive nitrogen species. Furthermore, Mediterranean diets can be a source of NFA. These highly electrophilic f
Externí odkaz:
https://doaj.org/article/3145053a7c004ee280edc9ef3a6adcaa
Autor:
Andreas von Knethen, Ulrike Heinicke, Volker Laux, Michael J. Parnham, Andrea U. Steinbicker, Kai Zacharowski
Publikováno v:
Biomedicines, Vol 10, Iss 1, p 98 (2022)
Acute respiratory distress syndrome (ARDS) is a major cause of patient mortality in intensive care units (ICUs) worldwide. Considering that no causative treatment but only symptomatic care is available, it is obvious that there is a high unmet medica
Externí odkaz:
https://doaj.org/article/d87cf02bb5ec4e5fa84681d1a96fed91
Autor:
Sandra Gunne, Ulrike Heinicke, Michael J. Parnham, Volker Laux, Kai Zacharowski, Andreas von Knethen
Publikováno v:
Biomolecules, Vol 10, Iss 12, p 1688 (2020)
The transcription factor NF-E2 p45-related factor 2 (Nrf2) is an established master regulator of the anti-oxidative and detoxifying cellular response. Thus, a role in inflammatory diseases associated with the generation of large amounts of reactive o
Externí odkaz:
https://doaj.org/article/316fa7eb89574b4f9e309b1fe3a1c4cf
Autor:
Katharina, Ruskowski, Holger, Neb, Steven R, Talbot, Suma, Choorapoikayil, Elisabeth H, Adam, Andreas, von Knethen, Kai, Zacharowski, Ulrike, Heinicke
Publikováno v:
American journal of respiratory cell and molecular biology. 67(3)
Autor:
Holger Neb, Kai Zacharowski, Steven R Talbot, Ulrike Heinicke, Suma Choorapoikayil, Elisabeth H Adam, Katharina Ruskowski, Andreas von Knethen
Background: Severe progression of coronavirus disease 2019 (COVID‑19) causes respiratory failure and critical illness. Recently, these pathologies have been associated with necroptosis, a receptor‑interacting serine/threonine‑protein kinase 3 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f13d18102f6b944da573920ee45f3992
https://doi.org/10.21203/rs.3.rs-1064345/v1
https://doi.org/10.21203/rs.3.rs-1064345/v1
Autor:
Andreas von Knethen, Kai Zacharowski, Ulrike Heinicke, Holger Neb, Elisabeth H Adam, Michael Sonntagbauer
Publikováno v:
Critical Care, Vol 24, Iss 1, Pp 1-4 (2020)
Critical Care
Critical Care
Critical care treatment of severely affected COVID-19 patients remains extremely challenging. To date, no experimental intervention has shown a significant benefit in this state of disease. Intravenous application of angiotensin II (ATII) has been po
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 2356, p 2356 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Regulatory T cells (Tregs) are important mediators of immunological self-tolerance and homeostasis. Being cluster of differentiation 4+Forkhead box protein3+ (CD4+FOXP3+), these cells are a subset of CD4+ T lymphocytes and can originate from the thym
Publikováno v:
Oncogene. 37:5325-5339
BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities. Previously, we demonstrated that JNJ-26481585 (JNJ), a second-generatio
Autor:
Simone Fulda, Meike Vogler, Michael Torsten Meister, Sara Fatima Faqar-Uz-Zaman, Ulrike Heinicke
Publikováno v:
Cancer Letters. 412:131-142
BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-xL, BCL-2 or MCL-1 (i.e. A-1331852, ABT-199, A-1210477) act in concert with multiple ch